Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors

J Med Chem. 2021 Jun 24;64(12):7991-8009. doi: 10.1021/acs.jmedchem.1c00217. Epub 2021 Jun 2.

Abstract

Macrocycles are typically cyclic variants of inhibitors derived from uncyclized canonical molecules or from natural products. For medicinal chemistry, drug-like macrocycles have received increasing interest over the past few years, since it has been demonstrated that macrocyclization can favorably alter the biological and physiochemical properties as well as selectivity in comparison to the acyclic analogue. Recent drug approvals such as Lorlatinib, glecaprevir, or voxilaprevir underline the clinical relevance of drug-like macrocycles. However, the synthesis of drug-like macrocycles can be challenging, since the ring-closing reaction is generally challenging with yields depending on the size and geometry of the bridging linker. Nevertheless, macrocycles are one opportunity to expand the synthetic toolbox for medicinal chemistry to provide bioactive molecules. Therefore, we reviewed the past literature of drug-like macrocycles highlighting reactions that have been successfully used for the macrocyclization. We classified the cyclization reactions by their type, ring-size, yield, and macrocyclization efficiency index.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Catalysis
  • Cell Line, Tumor
  • Cyclization
  • Humans
  • Macrocyclic Compounds / chemical synthesis*
  • Macrocyclic Compounds / pharmacology
  • Palladium / chemistry
  • Protein Kinase Inhibitors / chemical synthesis*
  • Protein Kinase Inhibitors / pharmacology

Substances

  • Macrocyclic Compounds
  • Protein Kinase Inhibitors
  • Palladium